

**deferasirox packet (JADENU SPRINKLE)**

**Diagnosis Considered for Coverage:**

- Chronic iron toxicity secondary to transfusional iron overload (transfusional hemosiderosis)

**Coverage Criteria:**

**For diagnosis listed above:**

- Intolerance or contraindication to deferasirox suspension tablet (Exjade) not expected with Jadenu Sprinkle, **and**
- Dose does not exceed 28 mg/kg per day.

**Coverage Duration:** one year

Effective Date: 11/30/2022